Syneos Health – Clinical Service Offering Analysis, CRO Strategic Positioning & H1 2023 Outlook

  • Credit
  • Healthcare
  • North America


Former executive at Syneos Health Inc


  • Recent trends and developments occurring within the CRO (contract research organisation) market coming out of the biotech funding slowdown and pandemic, focusing on Syneos Health (NASDAQ: SYNH)
  • Syneos’s end-to-end clinical and commercial solutions for biopharmaceutical development, highlighting strengths and weaknesses
  • Competitive landscape surrounding Syneos based on breadth of service offerings, leadership, pricing and innovation efforts, noting players such as Iqvia (NYSE: IQV), PPD and Icon (NASDAQ: ICLR)
  • Syneos’s DCT (decentralised clinical trial) capabilities – patient recruitment, traditional vs trial hybridisation, oncology and CNS (central nervous system) opportunities and technical advancements
  • 12-18-month CRO market outlook, noting partnership opportunities for Syneos and ability to sustain in an increasingly undifferentiated landscape


Gain access to Premium Content

Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.

    One week, unlimited access to over 40,000 transcripts
The information, material and content contained in this transcript (“Content”) is for information purposes only and does not constitute advice of any type or a trade recommendation and should not form the basis of any investment decision.This transcript has been edited by Third Bridge for ease of reading. Third Bridge Group Limited and its affiliates (together “Third Bridge”) make no representation and accept no liability for the Contentor for any errors, omissions or inaccuracies in respect of it. The views of the specialist expressed in the Content are those of the specialist and they are not endorsed by, nor do they represent the opinion of, Third Bridge. Third Bridge reserves all copyright, intellectual and other property rights in the Content. Any modification, reformatting, copying, displaying, distributing, transmitting, publishing, licensing, creating derivative works from, transferring or selling any Content is strictly prohibited